524. Hepatic Safety of Remdesivir Across Phase 3 Placebo-controlled COVID-19 Studies

por Force, Lindsey, Blair, Chris, Duckworth, Joshua, Abdelghany, Mazin, Nguyen, Ngoc-Quyen, Hyland, Robert H, Davies, Santosh, Chen, Shuguang, Zhao, Yang, Fu, Olivia
Publicado 2023

Pharmacokinetics, safety, and tolerability of inhaled remdesivir in healthy participants

por Humeniuk, Rita, Juneja, Kavita, Chen, Shuguang, Ellis, Scott, Anoshchenko, Olena, Xiao, Deqing, Share, Aaron, Johnston, Matthew, Davies, Santosh, DeZure, Adam, Llewellyn, Joe, Osinusi, Anu, Winter, Helen, Girish, Sandhya, Palaparthy, Ramesh, Dresser, Mark
Publicado 2023

Early Remdesivir to Prevent Progression to Severe Covid-19 in Outpatients

por Gottlieb, Robert L., Vaca, Carlos E., Paredes, Roger, Mera, Jorge, Webb, Brandon J., Perez, Gilberto, Oguchi, Godson, Ryan, Pablo, Nielsen, Bibi U., Brown, Michael, Hidalgo, Ausberto, Sachdeva, Yessica, Mittal, Shilpi, Osiyemi, Olayemi, Skarbinski, Jacek, Juneja, Kavita, Hyland, Robert H., Osinusi, Anu, Chen, Shuguang, Camus, Gregory, Abdelghany, Mazin, Davies, Santosh, Behenna-Renton, Nicole, Duff, Frank, Marty, Francisco M., Katz, Morgan J., Ginde, Adit A., Brown, Samuel M., Schiffer, Joshua T., Hill, Joshua A.
Publicado 2021